



# AA-Clozapine Patient Care Network - PATIENT REGISTRATION

Phone: 1-877-276-2569 / Fax: 1-866-836-6778 / Website: www.aaspire.ca

1165 Creditstone Rd., Unit 1, Vaughan, Ontario L4K 4N7

19-AA054\_AAC0350E1

## AA-CLOZAPINE ASSIGNED PIN:

--	--	--	--	--	--	--	--	--	--

FOR OFFICE USE ONLY

**The Physician is responsible for registering the Patient in the AA-Clozapine Patient Care Network. Please check one:**

- New Patient to AA-Clozapine  
  Patient Restart  
  Modify currently registered AA-Clozapine Patient  
  Discontinuation

## 1 PATIENT REGISTRATION (MASS TRANSFER SEE ATTACHED)

Initials:         Date of Birth:  /  /   
First Middle Last      DD    MMM    YYYY

Sex:  M     F     Other: \_\_\_\_\_

Ethnicity:  Caucasian     Asian  
 Black     Other (specify): \_\_\_\_\_

Status:  Inpatient     Outpatient     No interruption in treatment

Health Card #: \_\_\_\_\_

Monitoring Frequency:  Weekly     Biweekly     Every Four Weeks

## 3 PATIENT'S TREATMENT RESOURCE TEAM - PHYSICIAN REGISTRATION

Physician Name: \_\_\_\_\_

Physician License #:

Facility Name: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ Prov:   Postal Code:

Tel:    -    -     Ext: \_\_\_\_\_

Fax:    -    -

Email: \_\_\_\_\_

### Statement by Treating Physician

I, the treating physician, authorized nurse practitioner or authorized pharmacist\* will ensure that blood testing (white blood cell count and differential) for these patients (identified as per the list attached) as required by the AA-Clozapine Product Monograph is performed at the specified frequency. I understand that no pharmacy will dispense any brand other than AA-clozapine to my patients without my prior knowledge and permission regarding which brand is being dispensed. In this way I will be able to inform the laboratory to send my patients results to the appropriate manufacturer's clozapine database (AA-Clozapine Risk Management Program). I will not prescribe AA-Clozapine until the non-rechallengeable status of these patients has been verified. I have informed the patients and they have not objected to the release of relevant safety information held within a clozapine database to any other clozapine database of an approved manufacturer of clozapine in Canada, if needed for the safe utilization of this medication and/or for the continuous monitoring of these patients. The information which may be released, includes the non-rechallengeable/ hematological status of the patient, white blood cell counts and absolute neutrophil counts, dates and other information as may be relevant to the safe treatment of the patient with clozapine.

*\*In selected provinces, according to the College of Nurse, College of Pharmacy guidelines/regulations for applicable provinces*

← By selecting this box, I authorize the laboratory to release to AA-Pharma (1-866-836-6778) all hematological CBC and differential lab results for this patient.

Date:  /  /   
DD    MMM    YYYY

Physician's Signature: \_\_\_\_\_

## 2 PATIENT'S TREATMENT RESOURCE TEAM - PHARMACIST REGISTRATION

Pharmacist Name: \_\_\_\_\_

Pharmacist License #:

APA Designation:  Y     N

Pharmacy Name: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ Prov:   Postal Code:

Tel:    -    -     Ext: \_\_\_\_\_

Fax:    -    -

Email: \_\_\_\_\_

I confirm that all dispensing pharmacists at this location will only dispense AA-Clozapine at the specified frequency upon confirmation that the patient has had his/her blood drawn for a Complete Blood Count and differentials for the current period. If applicable, I also confirm responsibility for all actions undertaken by the website login.

Date:  /  /  Pharmacist's Signature: \_\_\_\_\_  
DD    MMM    YYYY

## 4 PATIENT'S TREATMENT RESOURCE TEAM - LABORATORY AND COORDINATOR REGISTRATION

Laboratory Name: \_\_\_\_\_

Address/City: \_\_\_\_\_

Tel:    -    -     Ext: \_\_\_\_\_

Fax:    -    -

Coordinator Name: \_\_\_\_\_

Site: \_\_\_\_\_

Address/City: \_\_\_\_\_

Tel:    -    -     Ext: \_\_\_\_\_

Fax:    -    -

**PLEASE NOTE: Please ensure AA Pharma is placed on the Standing Order/Requisition form so that we receive copies of the CBC results for the patient**

**TO COMPLETELY PROCESS NEW PATIENTS AND RESTARTS, CBC RESULTS WITH DIFFERENTIALS WITHIN THE LAST 30 DAYS ARE REQUIRED**

## DISCLOSURE

- a) I have reviewed and understand the AA-CLOZAPINE product monograph.
- b) I understand that death can occur as a result of agranulocytosis with the use of AA-CLOZAPINE, and that all patients on AA-CLOZAPINE must be enrolled in the AA-CLOZAPINE Patient Care Network to help reduce the risk of a nonrechallengeable patient using AA-CLOZAPINE. I understand that patients placed on the nonrechallengeable list have had previous unacceptable WBC counts, and/or ANC values, and/or Clozapine induced myocarditis as defined in the AA-CLOZAPINE product monograph.
- c) I understand that the patient's rechallengeable status will be verified prior to the initiation of treatment for all patients that are new to treatment, or for patients with an unknown or interrupted history on Clozapine.
- (d) I, the Physician, will only prescribe AA-CLOZAPINE following the receipt of aPIN number from the AA-CLOZAPINE Patient Care Network.
- (e) I agree to notify the AA-CLOZAPINE Patient Care Network of any discontinued patients or interruptions in AA-CLOZAPINE therapy.
- (f) I, the Physician, will ensure that if the patient is female, she is not pregnant nor breastfeeding.
- (g) I, the Pharmacist, will only dispense AA-CLOZAPINE following the receipt of aPIN number from the AA-CLOZAPINE Patient Care Network.
- (h) I, the Physician agree to ensure that hematological testing is performed at the required frequency (as per the product monograph) and submit copies of all lab reports indicating WBC and ANC results to AA Pharma within 7 days.
- (i) I agree to submit the four required weekly lab reports containing WBC and ANC counts after a patient discontinues Clozapine therapy.
- (j) I understand that the AA-CLOZAPINE Patient Care Network will monitor compliance with reporting requirements and will notify the patient's physician and/or pharmacist of any discrepancies or overdue lab reports.
- (k) In the event of agranulocytosis, clozapine induced myocarditis, or any other serious event, including any lack of drug effect and any clozapine related hospitalization I agree to fill out the required Serious Adverse Event form(s) and send this form(s) directly to AA-Clozapine Patient Care Network within 24 hours via fax to 18668366778 or report via phone to 18772762569.